Cargando…
Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigila...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369349/ https://www.ncbi.nlm.nih.gov/pubmed/32715108 http://dx.doi.org/10.1016/j.ctro.2020.06.013 |